The Smart MDI System in People With Type 1 Diabetes and High HBA1C: A Randomized Controlled Trial Demonstrating That Response to Alerts Drives Outcomes
Related Experiment Videos
Laurent Crenier1, Martin Haluzik2, Marcus Lind3,4
1Department of Endocrinology, HUB-Hôpital Erasme, Brussels, Belgium.
Aims:
The aim was to assess the efficacy and safety of the smart multiple daily injections (MDI) system versus MDI plus continuous glucose monitor (CGM) in people with Type 1 diabetes and HbA1c ≥ 8%.
Material And Methods:
After a 3-week run-in, 143 participants were randomized to Smart MDI or MDI + CGM. The primary endpoint was between-group difference (Δ) in time-in-range (TIR) at 6 months, adjusted for baseline glycaemia and assessed for non-inferiority (margin 7.5%). Secondary endpoints included HbA1c (non-inferiority margin 0.4%) and superiority analyses for TIR and HbA1c. Smart MDI alerts prompt insulin bolus actions (in contrast to traditional CGM alerts), and post hoc analyses were performed to evaluate 'alert-responsiveness' on glycaemia. Alert-responsiveness findings were validated in a real-world cohort of 5507 users. Safety endpoints were assessed.
Results:
At 6 months, Δ TIR between groups was 0.19 percentage points (95% confidence interval: -4.9 to 5.3), thus meeting non-inferiority; HbA1c also met non-inferiority (Δ: -0.13 percentage points, -0.46 to 0.19) but neither showed superiority. Post hoc analyses showed higher responders to alerts (those responding more than the median response rate of 28.3%, n = 31) had greater TIR gains than lower responders (n = 28) (+8.12 percentage points; p = 0.04) and HbA1c reduction (-0.6 percentage points; p = 0.02). TIR benefits in higher responders were confirmed in the real-world cohort. One episode of diabetic ketoacidosis occurred (run-in) and one severe hypoglycaemic event occurred (control arm).
Conclusions:
Smart MDI is safe and non-inferior, achieving non-inferiority to MDI + CGM regarding TIR and HbA1c. Responding to as few as 28% of alerts resulted in glycaemic improvements.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Type I Diabetes I: Introduction
Type II Diabetes I: Introduction